Mederi CE marks second-gen Secca and Stretta systems
This article was originally published in Clinica
Executive Summary
Mederi Therapeutics has CE marked its second-generation Stretta and Secca systems for sale in Europe. Stretta, a therapy for gastroesophageal reflux disease, involves insertion of the Stretta catheter through the patient’s mouth and into the valve between the stomach and oesophagus. Radiofrequency energy is delivered to the lower oesophageal sphincter and gastric cardia to create small thermal lesions. When these lesions heal, the tissue contracts, narrowing the opening to the oesophagus and preventing reflux. The Secca system is designed to treat bowel control disorder, or BCD. It uses a similar technique to contract the anal sphincter. These latest versions of the systems have an improved interface, are easier to use, and are smaller, lighter, and highly portable, the Greenwich, Connecticut firm says.